首页> 外文期刊>ACS medicinal chemistry letters >Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance
【24h】

Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance

机译:疟疾二氢酚酸还原酶的杂化抑制剂,具有防御性的双重结合模式

获取原文
获取原文并翻译 | 示例
           

摘要

The S108N mutation of dihydrofolate reductase (DHFR) renders Plasmodium falciparum malaria parasites resistant to pyrimethamine through steric clash with the rigid side chain of the inhibitor. Inhibitors with flexible side chains can avoid this clash and retain effectiveness against the mutant. However, other mutations such as N108S reversion confer resistance to flexible inhibitors. We designed and synthesized hybrid inhibitors with two structural types in a single molecule, which are effective against both wild-type and multiple mutants of P. falciparum through their selective target binding, as demonstrated by X-ray crystallography. Furthermore, the hybrid inhibitors can forestall resistant mutants, as shown by selection of mutants resistant to hybrid compound BT1 from a diverse PfDHFR random mutant library expressed in a surrogate bacterial system. These results show that it is possible to develop effective antifolate antimalarials to which the range of parasite resistance mutations is greatly reduced.
机译:二氢酚还原酶(DHFR)的S108N突变(DHFR)使疟原虫疟疾寄生虫通过与抑制剂的刚性侧链的空间冲突抵抗吡米甲酰胺。具有柔性侧链的抑制剂可以避免这种冲突并保持对突变体的有效性。然而,其他突变,例如N108S逆转赋予柔性抑制剂的抗性。我们在单个分子中设计和合成杂化抑制剂,其具有两个结构类型,其通过其选择性靶结合来对P. falciparum的野生型和多个突变体有效,如X射线晶体学证明。此外,杂交抑制剂可以防止抗抗突变体,如通过在替代细菌系统中表达的不同PFDHFR随机突变库中选择抗杂种化合物BT1的突变体。这些结果表明,可以开发有效的防雾抗疟药,寄生虫抗性突变的范围大大降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号